Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR) - Sabol - 2017 - Cancer Medicine - Wiley Online Library
Emerging Therapies for Progressive Multiple Sclerosis - Practical Neurology
Proposed Mechanism of Action (MOA) | TYSABRI® (natalizumab) HCP
Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
Current immunotherapies for multiple sclerosis and neuromyelitis optica spectrum disorders: the similarities and differences
References in Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines - Multiple Sclerosis and Related Disorders
Figure 1 | The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis | SpringerLink
Natalizumab for Multiple Sclerosis | NEJM
Identification and development of new therapeutics for multiple sclerosis: Trends in Pharmacological Sciences
Currently Approved Disease-Modifying Drugs: Monoclonal Antibody Natalizumab - ScienceDirect
Frontiers | Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies | Immunology
Natalizumab (Tysabri) | American Journal of Neuroradiology
Natalizumab and glatiramer acetate mechanism of action. A. Natalizumab... | Download Scientific Diagram
Multiple sclerosis and drug discovery: A work of translation - eBioMedicine
Natalizumab treatment of multiple sclerosis: new insights | Immunotherapy
Treating Multiple Sclerosis With Monoclonal Antibodies
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab | Nature Reviews Drug Discovery
Natalizumab (Tysabri). - Abstract - Europe PMC
Disease-modifying therapies for multiple sclerosis | The BMJ
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project - The Lancet Oncology
Frontiers | Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies | Immunology
Figure 3 from Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients | Semantic Scholar
Natalizumab (Tysabri) | American Journal of Neuroradiology
Aaron Boster MD on Twitter: "Click to learn how Tysabri (Natalizumab) works in #MS: https://t.co/TUYQqJTzQo #MultipleSclerosis #Tysabri https://t.co/WC7xvLO3EK" / Twitter
Natalizumab - Wikipedia
